Clinical Outcome of HIV-Infected Antiretroviral-Naive Patients With Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy
- 15 April 2008
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 47 (5), 553-558
- https://doi.org/10.1097/qai.0b013e31816856c5
Abstract
Background: The prognostic significance of a response to highly active antiretroviral therapy (HAART) that is immunologically and virologically discordant is not well understood. Methods: Four hundred four antiretroviral-naive patients initiating HAART at an urban HIV outpatient clinic in 1995 to 2004 were analyzed. The association of treatment responses at 3 to 9 months after HAART initiation with time to development of an opportunistic infection (OI) or death was determined using Cox proportional hazards modeling. Logistic regression modeling was used to examine the association between discordant responses and patient characteristics. Results: Of 404 patients, 70.5% experienced favorable concordant responses (CD4 cell count [CD4]+/viral load [VL]+: increase in CD4 count of ≥50 cells/μL and achievement of undetectable plasma HIV RNA level), 15.8% an immunologic response only (CD4+/VL−), 8.7% a virologic response only (CD4−/VL+), and 5.0% a concordant unfavorable response (CD4−/VL−). Both types of discordant responses (CD4+/VL− and CD4−/VL+), nonresponse (CD4−/VL−), and baseline CD4 cell count were significantly associated with earlier development of an OI or death (relative hazard [RH] = 2.81, 95% confidence interval [CI]: 1.31 to 3.97; RH = 4.83, 95% CI: 2.10 to 11.12; and RH = 0.93, 95% CI: 0.88 to 0.99, respectively). CD4+/VL− and CD4−/VL− were associated with nonwhite race in multivariate logistic regression models (adjusted OR = 2.83, 95% CI: 1.46 to 5.47 and adjusted OR = 6.50, 95% CI: 1.65 to 25.69, respectively). Conclusion: Discordant immunologic and virologic responses at 3 to 9 months after HAART initiation play important roles in predicting long-term clinical outcomes in treatment-naive patients.Keywords
This publication has 20 references indexed in Scilit:
- Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug usersAIDS Care, 2007
- Clinical outcome after 4 years follow‐up of HIV‐seropositive subjects with incomplete virologic or immunologic response to HAARTJournal of Medical Virology, 2005
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004
- Can Immune Markers Predict Subsequent Discordance between Immunologic and Virologic Responses to Antiretroviral Therapy? Adult AIDS Clinical Trials GroupClinical Infectious Diseases, 2003
- Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitor–Based Highly Active Antiretroviral Therapy: Immune Response and Viral ControlThe Journal of Infectious Diseases, 2003
- Contribution of Major Diseases to Disparities in MortalityNew England Journal of Medicine, 2002
- Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996–1998JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996–1998JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Long‐Term Clinical Outcome of Human Immunodeficiency Virus–Infected Patients with Discordant Immunologic and Virologic Responses to a Protease Inhibitor–Containing RegimenThe Journal of Infectious Diseases, 2001
- CD4 cell count as a surrogate endpoint in HIV clinical trialsAIDS, 1998